Theratechnologies Inc. - Asset Resilience Ratio
Theratechnologies Inc. (TH) has an Asset Resilience Ratio of 1.80% as of May 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Theratechnologies Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Theratechnologies Inc.'s Asset Resilience Ratio has changed over time. See Theratechnologies Inc. shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Theratechnologies Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Theratechnologies Inc. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$462.00K | 0.9% |
| Short-term Investments | CA$462.00K | 0.9% |
| Total Liquid Assets | CA$924.00K | 1.80% |
Asset Resilience Insights
- Limited Liquidity: Theratechnologies Inc. maintains only 1.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Theratechnologies Inc. Industry Peers by Asset Resilience Ratio
Compare Theratechnologies Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Theratechnologies Inc. (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Theratechnologies Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-11-30 | 13.96% | CA$7.45 Million ≈ $5.39 Million |
CA$53.34 Million ≈ $38.59 Million |
-2.22pp |
| 2023-11-30 | 16.18% | CA$12.58 Million ≈ $9.10 Million |
CA$77.77 Million ≈ $56.26 Million |
-3.58pp |
| 2022-11-30 | 19.76% | CA$18.43 Million ≈ $13.33 Million |
CA$93.26 Million ≈ $67.46 Million |
-13.72pp |
| 2021-11-30 | 33.48% | CA$39.91 Million ≈ $28.87 Million |
CA$119.21 Million ≈ $86.24 Million |
+17.44pp |
| 2020-11-30 | 16.04% | CA$16.06 Million ≈ $11.62 Million |
CA$100.14 Million ≈ $72.44 Million |
-4.32pp |
| 2019-11-30 | 20.35% | CA$23.93 Million ≈ $17.31 Million |
CA$117.56 Million ≈ $85.04 Million |
+2.92pp |
| 2018-11-30 | 17.43% | CA$19.39 Million ≈ $14.03 Million |
CA$111.25 Million ≈ $80.48 Million |
-38.28pp |
| 2017-11-30 | 55.71% | CA$33.03 Million ≈ $23.89 Million |
CA$59.29 Million ≈ $42.89 Million |
+43.17pp |
| 2016-11-30 | 12.54% | CA$4.95 Million ≈ $3.58 Million |
CA$39.43 Million ≈ $28.52 Million |
+4.93pp |
| 2014-11-30 | 7.61% | CA$2.17 Million ≈ $1.57 Million |
CA$28.51 Million ≈ $20.62 Million |
+7.21pp |
| 2013-11-30 | 0.40% | CA$93.25K ≈ $67.45K |
CA$23.40 Million ≈ $16.93 Million |
-0.01pp |
| 2012-11-30 | 0.41% | CA$150.00K ≈ $108.51K |
CA$36.58 Million ≈ $26.46 Million |
-1.01pp |
| 2011-11-30 | 1.42% | CA$728.26K ≈ $526.81K |
CA$51.20 Million ≈ $37.04 Million |
-1.17pp |
| 2010-11-30 | 2.60% | CA$1.82 Million ≈ $1.32 Million |
CA$70.28 Million ≈ $50.84 Million |
-11.85pp |
| 2009-11-30 | 14.44% | CA$9.49 Million ≈ $6.86 Million |
CA$65.70 Million ≈ $47.52 Million |
-5.79pp |
| 2008-11-30 | 20.23% | CA$8.82 Million ≈ $6.38 Million |
CA$43.60 Million ≈ $31.54 Million |
-16.59pp |
| 2007-11-30 | 36.82% | CA$27.45 Million ≈ $19.86 Million |
CA$74.55 Million ≈ $53.93 Million |
+1.46pp |
| 2006-11-30 | 35.36% | CA$15.79 Million ≈ $11.42 Million |
CA$44.65 Million ≈ $32.30 Million |
+12.03pp |
| 2005-11-30 | 23.33% | CA$10.72 Million ≈ $7.75 Million |
CA$45.93 Million ≈ $33.23 Million |
-2.44pp |
| 2004-11-30 | 25.77% | CA$14.75 Million ≈ $10.67 Million |
CA$57.23 Million ≈ $41.40 Million |
-15.78pp |
| 2003-11-30 | 41.55% | CA$30.28 Million ≈ $21.90 Million |
CA$72.88 Million ≈ $52.72 Million |
+13.72pp |
| 2002-11-30 | 27.83% | CA$24.98 Million ≈ $18.07 Million |
CA$89.78 Million ≈ $64.95 Million |
-6.75pp |
| 2001-11-30 | 34.58% | CA$31.25 Million ≈ $22.61 Million |
CA$90.38 Million ≈ $65.38 Million |
+2.10pp |
| 2000-11-30 | 32.48% | CA$17.86 Million ≈ $12.92 Million |
CA$54.99 Million ≈ $39.78 Million |
-48.33pp |
| 1999-11-30 | 80.81% | CA$14.87 Million ≈ $10.76 Million |
CA$18.40 Million ≈ $13.31 Million |
-- |
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more